Biotech entity
Every one of those 2 sits in a single category, fda-approval. CDC is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 94-day span, the pace is roughly 0.1 stories per week. Source depth averages 5 original sources per story, versus 3.6 across the same-window beat baseline.
Last mentioned: 2h ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, fda-approval. CDC is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 94-day span, the pace is roughly 0.1 stories per week. Source depth averages 5 original sources per story, versus 3.6 across the same-window beat baseline. At 5.5, the average consequence score sits below the same-window beat average of 6.1. This profile follows 2 Biotech stories mentioning American Medical Association across the period from June 12, 2026 to September 13, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 336 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering American Medical Association. Shared-story counts are live from our verified record — not editorial picks.
The FDA has cleared updated COVID-19 vaccines from Pfizer, Moderna, and Novavax for 2026-27, targeting the XFG/Stratus strain. The decision resets the competitive landscape for seasonal vaccine makers.
Source: eastbaytimes.com · marinij.com
Biopharma companies face a potentially shrinking market and tougher FDA standards after Senate testimony highlighted 'very low certainty evidence' for pediatric gender treatments. With systematic reviews failing to show robust benefit, pipeline programs and commercial prospects for puberty blockers and cross-sex hormones are at risk.
Source: Themercury · Ttownmedia
American Medical Association is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
